(CGEM) Cullinan Oncology - Ratings and Ratios

Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a biopharmaceutical company specializing in the development of innovative oncology therapies. The company focuses on advancing a diverse pipeline of cancer treatments, with a strong emphasis on solid tumors and hematological malignancies. Its lead candidate, CLN-619, is a monoclonal antibody currently in Phase I clinical trials for solid tumors, targeting specific pathways to enhance anti-tumor responses. The pipeline also includes CLN-049, a humanized bispecific antibody in Phase I trials for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), designed to target multiple antigens simultaneously for improved efficacy.

The company’s portfolio further expands with CLN-418, a human bispecific immune activator in Phase I trials for multiple solid tumors, leveraging its unique mechanism to stimulate immune responses against cancer cells. Additionally, Zipalertinib, a bioavailable small-molecule inhibitor, is being developed for non-small cell lung cancer (NSCLC) patients, addressing unmet needs in this indication. The pipeline is complemented by CLN-617, a fusion protein targeting solid tumors, and CLN-978, a T-cell engaging antibody for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). These programs underscore the company’s commitment to precision medicine and immune-oncology innovation.

Cullinan Therapeutics has established strategic collaborations to enhance its development capabilities. These include a license and collaboration agreement with Adimab, LLC, for antibody discovery and optimization, and a partnership with Harbour BioMed US Inc. for the development and commercialization of CLN-418. Additionally, the company has entered into a co-development agreement with Taiho Pharmaceutical Co., Ltd., for Zipalertinib, demonstrating its ability to form alliances to accelerate drug development. Formerly known as Cullinan Oncology, Inc., the company rebranded as Cullinan Therapeutics, Inc. in April 2024 to reflect its expanded therapeutic focus. Founded in 2016 and headquartered in Cambridge, Massachusetts, Cullinan Therapeutics is positioned as a key player in the oncology biopharma landscape.

Ticker Symbol: CGEM
Exchange: NASDAQ
Type: common stock
Country Origin: United States
GICS Sub Industry: Biotechnology
Web URL: https://cullinantherapeutics.com

Average Volume 20d: 422,198
Last Price: 8.61
SMA 20: 9.64
SMA 50: 10.62
SMA 200: 15.92
ATR: 0.64

Market Cap: 525.80M USD
P/E: 0.00
P/E Forward: 6.30
P/B: 0.85
P/S: 26.88
RoE: -22.86

3-Month Forecast:
Based on the technical and fundamental data, CGEM is expected to face resistance near its SMA 20 (9.64) and SMA 50 (10.62) levels. The stock may experience sideways movement with potential downside risks if it fails to reclaim these levels. The ATR of 0.64 suggests moderate volatility, with potential price fluctuations within a narrow range. Fundamental analysis indicates high valuation multiples, with a P/S ratio of 26.88, reflecting market expectations for long-term growth despite current losses (RoE: -22.86%). The forward P/E of 6.30 suggests investor optimism about future profitability. Overall, the stock is likely to remain under pressure in the near term, with potential stabilization if the company delivers positive clinical updates or strengthens its balance sheet.